Our Team

Advisors

Aykut Uren, MD

Cancer Recurrence Drug Discovery & Development

Professor, Department of Oncology, Department of Biochemistry and Molecular & Cellular Biology, Lombardi Comprehensive Cancer Center, Georgetown University.

Dalit Barkan, PhD

Cancer Recurrence Drug Discovery

Head, Laboratory of Tumor Dormancy and Metastasis, Department of Human Biology and Medical Sciences, Faculty of Natural Sciences, University of Haifa, Israel.

George Sledge, MD

Medical Advisor

Chief of Oncology, Department of Medicine, Stanford University. Former president of the American Society for Clinical Oncology.

Gil Ben Menachem, PhD

Product Innovation, Business Development and Strategy

Experienced biopharma executive. CEO, Neuromagen Pharma, Teva, Dexcel, Kitov, Paramount Bio and the NIH.

Mike Ihnat, PhD

Cancer Recurrence Biology & Drug Discovery

Associate Professor, Pharmacology, Department of Pharmaceutical Sciences University of Oklahoma College of Pharmacy, OK

Peter C. Scacheri, PhD

Cancer Epigenomics

Professor, Department of Genetics and Genome Sciences, School of Medicine
Member, Cancer Genomics Program, Case Comprehensive Cancer Center.

Rafael Torgovicky, MD

Product Innovation, Business Development and Strategy

Experienced biopharma executive. Formally Novartis, Merck & Co, and Vice President, External Innovation – Oncology at Eli Lilly and Company.